Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferrisat versus placebo for iron deficiency anemia in inflammatory bowel disease on anti-TNF alpha therapy
2009-011316-38Phase 3Active
- Sponsor
- GETAID
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD) comparing Ferrisat IV arm with Placebo IV arm (2 arms). Primary endpoint: Intravenous iron treatment response. Started Jul 2010; status: active.
02
Drugs
iron sucrose
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2009-011316-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011316-38.